Title | Author(s) | Issue date | ???itemlist.??? |
Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study | Fountzilas, G.; Stathopoulos, G.; Kouvatseas, G.; Polychronis, A.; Klouvas, G.; Samantas, E.; Zamboglou, N.; Kyriakou, K.; Adamou, A.; Pectasidis, D.; Ekonomopoulos, T.; Kalofonos, H. P.; Bafaloukos, D.; Georgoulias, V.; Razis, E.; Koukouras, D.; Zombolas, V.; Kosmidis, P.; Skarlos, D.; Pavlidis, N. | 24-Nov-2015 | - |
Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer | Razis, E.; Dimopoulos, A. M.; Bafaloukos, D.; Papadimitriou, C.; Kalogera-Fountzila, A.; Kalofonos, H.; Briassoulis, E.; Samantas, E.; Keramopoulos, A.; Pavlidis, N.; Kosmidis, P.; Fountzilas, G. | 24-Nov-2015 | - |
Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group | Fountzilas, G.; Papadimitriou, C.; Dafni, U.; Bafaloukos, D.; Skarlos, D.; Moulopoulos, L. A.; Razis, E.; Kalofonos, H. P.; Aravantinos, G.; Briassoulis, E.; Papakostas, P.; Abela, K.; Gogas, E.; Kosmidis, P.; Pavlidis, N.; Dimopoulos, M. A. | 24-Nov-2015 | - |
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study | Koutras, A. K.; Kalogeras, K. T.; Dimopoulos, M. A.; Wirtz, R. M.; Dafni, U.; Briasoulis, E.; Pectasides, D.; Gogas, H.; Christodoulou, C.; Aravantinos, G.; Zografos, G.; Timotheadou, E.; Papakostas, P.; Linardou, H.; Razis, E.; Economopoulos, T.; Kalofonos, H. P.; Fountzilas, G. | 24-Nov-2015 | - |
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study | Skarlos, D. V.; Kalofonos, H. P.; Fountzilas, G.; Dimopoulos, M. A.; Pavlidis, N.; Razis, E.; Economopoulos, T.; Pectasides, D.; Gogas, H.; Kosmidis, P.; Bafaloukos, D.; Klouvas, G.; Kyratzis, G.; Aravantinos, G. | 24-Nov-2015 | - |
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation | Fountzilas, G.; Kourea, H. P.; Bobos, M.; Televantou, D.; Kotoula, V.; Papadimitriou, C.; Papazisis, K. T.; Timotheadou, E.; Efstratiou, I.; Koutras, A.; Pentheroudakis, G.; Christodoulou, C.; Aravantinos, G.; Miliaras, D.; Petraki, K.; Papandreou, C. N.; Papakostas, P.; Bafaloukos, D.; Repana, D.; Razis, E.; Pectasides, D.; Dimopoulos, A. M. | 24-Nov-2015 | - |
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group | Fountzilas, G.; Pectasides, D.; Kalogera-Fountzila, A.; Skarlos, D.; Kalofonos, H. P.; Papadimitriou, C.; Bafaloukos, D.; Lambropoulos, S.; Papadopoulos, S.; Kourea, H.; Markopoulos, C.; Linardou, H.; Mavroudis, D.; Briasoulis, E.; Pavlidis, N.; Razis, E.; Kosmidis, P.; Gogas, H. | 24-Nov-2015 | - |
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group | Fountzilas, G.; Kalofonos, H. P.; Dafni, U.; Papadimitriou, C.; Bafaloukos, D.; Papakostas, P.; Kalogera-Fountzila, A.; Gogas, H.; Aravantinos, G.; Moulopoulos, L. A.; Economopoulos, T.; Pectasides, D.; Maniadakis, N.; Siafaka, V.; Briasoulis, E.; Christodoulou, C.; Tsavdaridis, D.; Makrantonakis, P.; Razis, E.; Kosmidis, P.; Skarlos, D.; Dimopoulos, M. A. | 24-Nov-2015 | - |
Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety | Pentheroudakis, G.; Razis, E.; Athanassiadis, A.; Pavlidis, N.; Fountzilas, G. | 24-Nov-2015 | - |
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group | Fountzilas, G.; Skarlos, D.; Dafni, U.; Gogas, H.; Briasoulis, E.; Pectasides, D.; Papadimitriou, C.; Markopoulos, C.; Polychronis, A.; Kalofonos, H. P.; Siafaka, V.; Kosmidis, P.; Timotheadou, E.; Tsavdaridis, D.; Bafaloukos, D.; Papakostas, P.; Razis, E.; Makrantonakis, P.; Aravantinos, G.; Christodoulou, C.; Dimopoulos, A. M. | 24-Nov-2015 | - |
Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study | Razis, E.; Briasoulis, E.; Vrettou, E.; Skarlos, D. V.; Papamichael, D.; Kostopoulos, I.; Samantas, E.; Xanthakis, I.; Bobos, M.; Galanidi, E.; Bai, M.; Gikonti, I.; Koukouma, A.; Kafiri, G.; Papakostas, P.; Kalogeras, K. T.; Kosmidis, P.; Fountzilas, G. | 24-Nov-2015 | - |
Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation | Christodoulou, C.; Kostopoulos, I.; Kalofonos, H. P.; Lianos, E.; Bobos, M.; Briasoulis, E.; Gogas, H.; Razis, E.; Skarlos, D. V.; Fountzilas, G. | 24-Nov-2015 | - |
Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program | Razis, E.; Skarlos, D.; Briasoulis, E.; Dimopoulos, M.; Fountzilas, G.; Lambropoulos, S.; Rigatos, S.; Kopterides, P.; Efstathiou, H.; Tzamakou, E.; Bakoyannis, C.; Pectasides, D.; Makatsoris, T.; Varthalitis, G.; Papadopoulos, S.; Kosmidis, P. | 24-Nov-2015 | - |